Results 211 to 220 of about 47,798 (276)

The Relationships between HER2 Overexpression and DCIS Characteristics

Breast Journal, 2017
The aim of this study was to demonstrate the correlation between human epidermal growth factor receptor 2 (HER2) overexpression and some poor prognosis factors in patients affected by ductal carcinoma in situ (DCIS).
Laura Villani, Gian Antonio Da Prada, Alberto Riccardi   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Current Therapeutic Approaches to DCIS

Journal of Mammary Gland Biology and Neoplasia, 2018
Treatment for ductal carcinoma in-situ (DCIS) has historically been extrapolated from studies of invasive breast cancer. Accepted local therapy approaches range from small local excisions, with or without radiation, to bilateral mastectomies. Systemic treatment with endocrine therapy is often recommended for hormone positive patients. With improvements
K. Doke, Shirley Butler, M. Mitchell
semanticscholar   +3 more sources

Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trial

European Journal of Cancer, 2023
Background Ductal carcinoma in situ (DCIS) can progress to invasive breast cancer (IBC), but most DCIS lesions remain indolent. However, guidelines recommend surgery, often supplemented by radiotherapy. This implies overtreatment of indolent DCIS.
Ellen Verschuur
exaly   +2 more sources

Archival single cell genomics reveals persistent subclones during DCIS progression

Cell, 2023
Summary Ductal carcinoma in situ (DCIS) is a common precursor of invasive breast cancer. Our understanding of its genomic progression to recurrent disease remains poor, partly due to challenges associated with the genomic profiling of formalin-fixed ...
Kaile Wang, T. Kumar, Junke Wang, Darlan C Minussi, Emi Sei, Jianzhuo Li, Tuan M. Tran, A. Thennavan, Min Hu, Anna Casasent, Zhenna Xiao, S. Bai, Lei Yang, Lorraine M. King, Vandna Shah, P. Kristel, C. L. van der Borden, J. Marks, Yuehui Zhao, A. Zurita, A. Aparicio, B. Chapin, Jie-Tong Ye, Jianjun Zhang, D. Gibbons, Ellinor Sawyer, A. Thompson, A. Futreal, E. S. Hwang, J. Wesseling, E. Lips, N. Navin   +31 more
semanticscholar   +1 more source

The clinical significance of HER2 expression in DCIS

Medical Oncology, 2022
Ioanna Akrida
exaly   +2 more sources

Advances and controversies in management of breast ductal carcinoma in situ (DCIS).

European Journal of Surgical Oncology, 2021
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast cancers diagnosed, as a result of the expansion of breast cancer screening and is associated with a high survival rate.
G. Farante, A. Toesca, F. Magnoni, G. Lissidini, J. Vila, M. Mastropasqua, G. Viale, S. Penco, E. Cassano, M. Lazzeroni, B. Bonanni, M. Leonardi, Francisco Ripoll-Orts, G. Curigliano, R. Orecchia, V. Galimberti, P. Veronesi   +16 more
semanticscholar   +1 more source

Addressing overtreatment of screen detected DCIS; the LORIS trial

European Journal of Cancer, 2015
Overdiagnosis, and thus overtreatment, are inevitable consequences of most screening programmes; identification of ways of minimising the impact of overdiagnosis demands new prospective research, in particular the need to separate clinically relevant ...
Adele Francis, Jeremy Thomas, Lesley Fallowfield   +2 more
exaly   +2 more sources

DCIS and aromatase inhibitors

The Journal of Steroid Biochemistry and Molecular Biology, 2007
In patients with hormone receptor positive DCIS tamoxifen reduces recurrence rates by almost 50%. Few data are available with aromatase inhibitors from randomised studies. In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer. In the MA17 study which randomised
J Michael, Dixon, Dana, Faratian, Sharon, White, Lorna, Renshaw, Juliette, Murray, Oliver, Young, E Jane, Macaskill, Linda, Williams, Jeremy, Thomas, Dean B, Evans   +9 more
openaire   +2 more sources

The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA).

Journal of Clinical Oncology, 2019
TPS603 Background: Retrospective data suggest breast cancer-specific survival rates with versus without surgery in patients with low-grade ductal carcinoma in situ (DCIS) are similar.
C. Kanbayashi, A. Thompson, E. Hwang, A. Partridge, D. Rea, J. Wesseling, T. Shien, T. Mizutani, T. Shibata, H. Iwata   +9 more
semanticscholar   +1 more source

Abstract P3-14-03: Differences in pathological and biological factors between DCIS, DCIS with microinvasion (DCIS-MI) and DCIS with concomitant invasive ductal carcinoma (DCIS-IDC).

Cancer Research, 2012
Abstract Background: Specific pathological and biological factors differentiating pure DCIS, DCIS with microinvasion (DCIS-MI) and DCIS with concomitant invasive ductal carcinoma (DCIS-IDC) are currently unknown. Identification of such factors would enable us to better understand the transition from an in situ to an invasive carcinoma ...
G MacGrogan, MC Baranzelli, JM Picquenot, F Penault-Llorca, MC Mathieu, P Tas, V Fermeaux, E Mery, C Sagan, C Blanc-Fournier, E Brabencova, L Arnould, J Jacquemier, F Ettore, V Velasco, B Gonzalves, V Brouste, de Lara C Tunon   +17 more
openaire   +1 more source